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Guideline
The Committee on Dyslipidemia of Korean Pediatric and 
Adolescents of the Korean Society of Pediatric Endocrinology 
has newly developed evidence-based clinical practice guide-
lines for dyslipidemia in Korean children and adolescents. 
These guidelines were formulated with the Grading of Recom-
mendations, which include both the strength of recommen-
dations and the quality of evidence. In the absence of sufficient 
evidence, conclusions were based on expert opinion. These 
guidelines are based on the 2011 National Heart, Lung, and 
Blood Institute Guidelines, which focus on the prevention 
of cardiovascular disease in children and draw from a com-
prehensive review of evidence. These guidelines contain the 
definition of and screening process for dyslipidemia and in-
troduce new dietary methods: the Cardiovascular Health 
Integrated Lifestyle Diet (CHILD)-1, the CHILD-2-low-den-
sity lipoprotein cholesterol, and the CHILD-2-triglyceride. 
Potential drug therapies for dyslipidemia along with their main 
effects and doses were also included.
Key words: Practice guidelines, Dyslipidemia, Child, Adole-
scent, Korea
Key message
Question: How are children and adolescents with dyslipidemia 
treated and managed in Korea?
Finding: 2017 guidelines recommend to measure nonfasting 
non-HDL-C as a screening test and introduce new diet 
methods: Cardiovascular Health Integrated Lifestyle Diet 
(CHILD)-1, CHILD-2-low-density lipoprotein cholesterol, 
and CHILD-2-triglyceride. Statin is the only drug approved in 
children older than 10 years.
 Meaning: New clinical practice guidelines for treating and 
managing dyslipidemia of Korean children and adolescents 
are provided.
Introduction
Cardiovascular disease (CVD) is a major cause of morbidity 
and mortality worldwide, including in Korea.1,2) The prevalence 
of CVD in Korea has historically been much lower than the rate 
reported in Western countries. Recently, however, the CVD-
associated mortality rate in Korea has increased to 27.6%, which 
is comparable to that in the United States (US).2) 
Increased total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C), triglyceride (TG), and decreased high-
density lipoprotein cholesterol (HDL-C) are well-known risk 
factors associated with CVD.3-6) The Korean Heart Study, a 10-
year prospective study of 430,920 adult men and women, also 
concluded that high TC and low HDL-C levels increased the risk 
of CVD.7) 
Dyslipidemia is closely related to other CVD risk factors, 
such as hypertension, obesity, and smoking status, not only in 
adults but also in children and adolescents.3,8) Furthermore, the 
prevalence of obesity and metabolic syndrome, which are other 
risk factors for CVD, has steadily increased in Korea and is now 
comparable to the rate reported in the US.6,9) This trend likely 
resulted from recent changes in dietary habits among Korean 
people that are commonly associated with a western lifestyle.9,10)
Although CVD does not usually develop until the fourth 
decade of life, it is well known that atherosclerosis begins in 
childhood.8,11,12) The initial stages of atherosclerosis and its 
progression are associated with dyslipidemia.13) Autopsy data 
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from the Pathobiological Determinants of Atherosclerosis in 
Youth Study showed a strong correlation between high chole-
sterol and the development of fatty streaks and fibrous plaques 
in coronary vasculature at an early age.14) In the Bogalusa Heart 
Study, the extent of fatty streaks and fibrous plaques increased 
with age and was correlated with antecedent serum TG, very-
high LDL-C, and obesity.3)
Among Korean children and adolescents aged 10–19 years, 
20% had at least one type of dyslipidemia.15) The prevalence of 
hypercholesterolemia, high LDL-C, high TG, and low HDL-C 
concentrations among Korean children and adolescents was 
6.5%, 4.7%, 10.1%, and 11.9%, respectively.16) The rate of 
dyslipidemia in Korean obese adolescents has been reported as 
56.1%.15) 
Early recognition of and intervention for dyslipidemia in 
Korean children and adolescents is important for preventing 
CVD later in life. In this context, the Committee on Pediatric 
Dyslipidemia of the Korean Society of Pediatric Endocrinology 
(KSPE) has recently developed evidence-based clinical practice 
guidelines to treat dyslipidemia in Korean children and adole-
scents.
Definition of dyslipidemia
Several studies, such as the Lipid Research Clinics Prevalence 
Study and the National Health and Nutrition Examination Sur-
vey, have shown that there are sexual, racial, and ethnic differ-
ences in lipid profiles and also in the overall prevalence of dysli-
pi demia.17,18) The mean and 50th percentiles for TC, LDL-C, 
non-HDL-C, TG, and HDL-C were similar between Koreans and 
Caucasians from the US.17,18) According to the Korea National 
Health and Nutrition Examination Survey IV (2007–2009), the 
95th percentiles for TC and LDL-C and the 10th percentile for 
HDL-C in Korean children and adole scents aged 10–18.9 years 
were 203 mg/dL, 129 mg/dL, and 38 mg/dL, respectively. The 
90th and 95th percentiles for TG concentrations were 150 and 
185 mg/dL, respectively. In addition, a non-HDL-C of 145 mg/dL 
corresponds to approxi mately the 90th to 95th percentiles.15,19)
The Committee of Clinical Practice Guidelines of the KSPE 
decided to adopt the National Heart Lung and Blood Institute 
(NHBLI) 2011 guidelines for dyslipidemia to prevent adulthood 
CVD by lifestyle modification or medical intervention.20) The 
cutoff levels for serum lipid levels to diagnose dyslipidemia in 
Korean children and adolescents are listed and defined in Table 1.
There have been controversies in the optimum TG cutoff 
level. Because carbohydrates make up a major part of the Korean 
traditional diet, some researchers have insisted that a higher TG 
concentration of 150 mg/dL, which corresponds to the 90th 
percentile of Korean adolescents, is more appropriate in defining 
dyslipidemia.15) However, recent studies have shown that the 
consumption of simple sugars, fructose, and alcohol is a main 
factor that increases TG levels.21,22) Furthermore, because TG 
is the main target of lifestyle modification in dyslipidemia, we 
decided to define hypertriglyceridemia as a TG concentration > 
130 mg/dL. For Korean children younger than 10 years of age, 
further studies will be required to determine more appropriate 
reference and cutoff points for dyslipidemia. 
According to the cutoff points of the NHBLI guidelines, 
19.7% of Korean children and adolescents from 10–18 years 
of age had at least one abnormal lipid concentration.15) The pre-
valence of hypercholesterolemia, high LDL-C, high TG, and 
low HDL-C (<40 mg/dL) was 6.5% (5.8% in males, 7.4% in 
females), 4.7% (4.1% in males, 5.5% in females), 10.1% (9.8% 
in males, 10.3% in females), and 11.9% (14.5% in males, 9.5% 
in females), respectively.15,16) The prevalence of dyslipidemia 
was 20.7%, 39.6%, and 56.1% for boys (and 24.5%, 36.6%, 
and 53.1% for girls) who were normal weight, overweight, and 
obese, respectively.16)
Screening recommendations
Screening for lipids in children is based on the rationale that 
early identification and control of pediatric dyslipidemia will 
reduce the risk and severity of CVD in adulthood. Therefore, the 
Committee of Clinical Practice Guidelines of KSPE recommends 
“universal screening.” Universal screening in this guideline might 
be performed to detect those with undiagnosed heterozygous 
familial hypercholesterolemia who would require more intensive 
treatment, possibly including pharmacological therapy.20,23) In 
contrast, targeted screening based on family history of CVD or 
hypercholesterolemia fails to detect a substantial number (from 
30%–60%) of children with elevated lipid levels.24) Almost 51% 
of untreated children with dyslipidemia will go on to develop 
clinical CVD by 50 years of age, and 5% do so by 30 years of 
age.25)
Universal lipid screening should be performed with the 
measurement of nonfasting non-HDL-C in all children aged 
9–11 and 17–21 years. Non-HDL-C is calculated as follows: non-
HDL-C=TC–HDL-C. Non-HDL-C includes all cholesterol 
types present in lipoprotein particles (LDL-C, lipopro tein(a), 
Table1. Definition of dyslipidemia in children and adolescents   
Variable Acceptable Borderlinea) Abnormalb)
Total cholesterol (mg/dL) <170 170–199 ≥200
LDL-C (mg/dL) <110 110–129 ≥130
Non–HDL-C (mg/dL) <120 120–144 ≥145
Triglyceride (mg/dL)
0–9 years <75 75–99 ≥100
10–19 years <90  90–129 ≥130 
HDL-C (mg/dL) >45 40–45 <40
LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non–high-density 
lipoprotein cholesterol; HDL-C, high-density lipoprotein.
a)Borderline values of total cholesterol and LDL-C represent the 75th–95th 
percentile. b)Abnormal values of total cholesterol and LDL-C represent the 
95th percentile, except for HDL-C which represents the 10th percentile.16)
Adapted from National Heart, Lung, and Blood Institute 2011.20)
Non-HDL-C=TC–HDL-C.
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intermediate density lipoprotein, and very-low-density lipopro-
tein) that are considered atherogenic. Therefore, non-HDL-C is 
a better independent predictor of CVD than LDL-C and is also 
as good a predictor of future adulthood dyslipidemia that can 
replace LDL-C.26-28) If non-HDL-C is >145 mg/dL, 2 additional 
fasting lipid panels (at least 2 weeks but no more than 12 weeks 
apart) should be obtained and the average values are used. 
Screening for dyslipidemia is not recommended until 2 years 
of age. For children aged 2–8 and 12–16 years, routine lipid 
screening is also not recommended. Targeted screening is only 
encouraged if there is a family history of high cardiovascular 
risk or other risk factors and conditions. The risk factors and 
conditions to consider for the screening and treatment decisions 
in children with dyslipidemia are included in Tables 2 and 3.20)
Management 
Rising rates of dyslipidemia in Korean children and adoles-
cents might be due to increases in adoption of the western life-
style, especially the westernized diet and decrease in physical 
activity.29,30) Therefore, lifestyle modifications, such as promo-
ting a healthy diet and regular physical activity, are thought to 
be essential in treating dyslipidemia. The algorithm used for 
dyslipidemia management is shown in Fig 1. 
1. Lifestyle change and diets 
The KSPE guidelines recommend that all children and 
adolescents engage in moderate-to-vigorous physical activity for 
at least one hour a day and limit sedentary activity, including tele-
vision, internet, and video games, to <2 hours a day. Cigarette 
exposure also should be strongly discouraged. In addition, 
all children and adolescents should try to attain an ideal body 
weight (body mass index ≤85th percentile for age and sex). 
Any diet change must provide optimal nutrition for growth 
and development. The 2010 Dietary Guidelines for Americans 
recommend the Cardiovascular Health Integrated Lifestyle Diet 
(CHILD-1) be used in children and adolescents 2 years of age or 
older who are at risk for CVD.31) 
Exclusively breastfeeding should be done until 6 months of 
age. If direct breastfeeding is impossible, use a breast pump, and 
if any breastfeeding is not available, iron-fortified infant formula 
Table 2. Risk factors of dyslipidemia
Family history
Parent, grandparent, aunt, or uncle with a history of myocardial infarction, angina pectoris, coronary artery bypass/stent/angioplasty, sudden death 





High risk conditions: type 1 diabetes mellitus, type 2 diabetes mellitus, chronic kidney disease/end stage renal failure/kidney transplantation, heart 
transplantation, Kawasaki disease with aneurysm
Moderate-level risk factors
Hypertension not requiring medication
95th percentile≤BMI<97th percentile
HDL cholesterol<40 mg/dL
Moderate risk conditions: Kawasaki disease with improved coronary artery aneurysm, chronic inflammatory disease (systemic lupus erythematosus, 
infantile rheumatoid arthritis), human immunodeficiency virus infection, nephrotic syndrome
BMI, body mass index; HDL, high-density lipoprotein.
Table 3. Screening for dyslipidemia
Age Recommendation
Birth–2 yr No lipid screening
2–8 yr No routine lipid screening 
Measure fasting lipid profile if child has a family history of dyslipidemia, moderate or high-risk factors and conditiona) 
9–11 yr Universal screening 
Measure nonfasting non–HDL-C
Fasting lipid testing if non-HDL-C≥145 mg/dLa)
12–16 yr No routine lipid screening 
Measure fasting lipid profile if child has a family history of dyslipidemia, moderate or high-risk factors and conditiona) 
17–21 yr Universal screening 
Measure nonfasting non-HDL-C
Fasting lipid testing if non-HDL-C≥145 mg/dLa)
HDL-C, high-density lipoprotein cholesterol.
a)Two additional fasting lipid tests measured 2 weeks but within 3 months.  
www.e-cep.org https://doi.org/10.3345//cep.2020.01340 457
should be fed. Breastfeeding should continue for at least 12 
months while gradually adding solids. If breast milk decreases, 
feed iron-fortified formula until 12months. Infants under 12 
months of age should not limit their fat intake without medical 
indication and limit 100% juice to about 120 mL per day, drink 
water without any other beverages.  
Consult health-care provider about low-fat milk intake after 
12 months of age if a family history of obesity, heart disease, or 
dyslipidemia is present.20)
If the fasting lipid profile findings exceed the therapeutic goals 
after a 3-month trial of the CHILD-1 diet, then the CHILD-2-
LDL, or CHILD-2-TG diet should be recommended based on 
specific abnormal lipid parameters. 
The detailed contents of each diet are listed in Table 4. The 
CHILD-1 urges specific protocols: drink fat-free unflavored milk 
primarily, limit/avoid sugar-sweetened beverages, encourage 
water consumption, limited total fat content (25%–30% of the 
daily kcal/estimated energy requirements [EER] per day for age/
gender), limit saturated fat 8%–10% of the daily kcal/EER, avoid 
transfat as much as possible, and recommend monounsaturated 
and polyunsaturated fat up to 20% of the daily kcal/EER, and 
limit cholesterol intake to <300 mg/day.20) In addition, these re-
commendations advocate the intake of dietary fiber (14 g/1,000 
kcal), limiting naturally sweetened juice (no added su gar) to 120 
mL/day, limiting sodium intake, and encouraging healthy eating 
habits overall. The CHILD-2 is divided into CHILD-2-LDL and 
CHILD-2-TG guidelines depending on the dyslipidemia target. 
Above all, it is important to refer these children and adolescents 
to a registered dietitian for family-based medical nutrition the-
rapy and to decrease their total sugar intake. The CHILD-2 diet 
recommends the following: avoiding transfats, consuming <200 
mg/day of cholesterol, and sustaining total, saturated, and mono-
unsaturated fat at 25%–30%, 7%, and <10% of total calories, 
respectively. Supportive dietary plans are different between the 
CHILD-2-LDL and the CHILD-2-TG. The CHILD-2-LDL diet 
recommends phytosterols up to 2 g per day as substitutes for 
dietary fats in children with familial hypercholesterolemia who 
are older than 2 years. Water-soluble fiber, such as psyllium, can 
be added to a low-fat, low-saturated fatty acid diet (6 g/day for 
children from 2–12 years and 12 g/day for children >12 years). 
With the CHILD-2-TG, an increase in fish intake is critical in 
improving the levels of omega-3 fatty acids. TG levels are very 
responsive to weight loss, diet com position, and exercise.32)
2. Drug therapy
Decisions regarding the need for drug therapy should be based 
on the average values from at least 2 fasting lipid tests obtained at 
least 2 weeks but no more than 3 months apart.  
Drug therapy is recommended in children ≥10 years with 
a poor response to diet and lifestyle therapy for at least 6–12 
LDL-C≥250 mg/dL → Request to specialist 
130≤TG<500 mg/dL
(100≤ for younger than 10 yr of age)
130≤LDL<250 mg/dL
TG≥500 mg/dL → Request to specialist 
Secondary cause exclusion, risk evaluation
CHILD 1 for 6 mo → CHILD 2-LDL + 
Lifestyle modification
CHILD 1 for 6 mo → CHILD 2-TG + lifestyle 
modification with weight loss
LDL-C<130 mg/dL
Continue CHILD 2-LDL,
FLP every 1 yr
TG<130 mg/dL
(TG<100 for younger 
than 10 yr of age)
Continue CHILD 2-TG,
FLP every 1 yr
TG 130-199 mg/dL
(TG 100-199 for younger 
than 10 yr of age)
CHILD 2-TG and 
reinforce weight loss
Increase fish intake




omega-3 fatty acid  
LDL-C 130-189 mg/dL
Family history(-), Risk 
factor(-)
Continue CHILD 2-LDL,
FLP every 6 mo
LDL-C≥190 mg/dL
LDL-C 160-189 mg/dL
Family history(+), ≥1 high-risk factor, or 
≥2 moderate-risk factors
LDL-C 130-159 mg/dL
≥2 high-risk factors, 1 high-risk factor + 
≥2 moderate-risk factors, or clinical CVD
Statin treatment
If LDL-C <130 mg/dL but non-HDL-C ≥145 
mg/dL, consider statin, fibrate, or niacin 
FLP average value
(at least 2 times)
Fig. 1. Algorithm for dyslipidemia treatment. FLP, fasting lipid profile; LDL-C, low-density lipoprotein cholesterol; CHILD 1, Cardiovascular Health 
Integrated Lifestyle Diet 1; CHILD 2-LDL, Cardiovascular Health Integrated Lifestyle Diet 2; non-HDL-C, non–high-density lipoprotein cholesterol; 
TG, triglycerides; CVD, cardiovascular disease.
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months.20) The choice of medication depends on the lipid profile, 
age, sex, family history, and the pediatricians’ experience.33) In 
Korea, at least 0.41% of Korean children and adolescents are 
candidates for pharmacological treatment.16) 
Children with average LDL-C levels ≥250 mg/dL or TG≥ 
500 mg/dL should be referred directly to a lipid specialist. If the 
TG concentration is >500 mg/dL, there is a risk of pancreatitis, 
and specialist consultation is therefore necessary.34)
Statin treatment is generally not started in children under the 
age of 10, and it is limited to patients homozygous for familial 
hypercholesterolemia or with LDL-C≥400 mg/dL, primary 
hypertriglyceridemia≥500 mg/dL, CVD, or cardiac transplan-
tation.
If the LDL-C remains ≥190 mg/dL after a 6-month trial of 
lifestyle management (CHILD-1 → CHILD-2-LDL) for children 
aged 10 years and older, statin therapy should be considered.20,35) 
For patients with an LDL-C concentration between 160–189 
mg/dL, statin treatment should be considered if there is a positive 
family history of premature CVD in first-degree relatives, at least 
one high-level risk factor or risk condition, or at least 2 moderate-
level risk factors or risk conditions. If the LDL-C concentration is 
between 130–159 after 6 months of lifestyle modification, and 
if the children have at least 2 high-risk factors or conditions or 
at least one high-level risk factor and two or more moderate-risk 
factors or conditions or clinical CVD, statin therapy should be 
considered.
In children who are at least 10 years of age, the administration 
of statins, fibrates, or niacin may be considered if the LDL-C has 
reached its target but the non-HDL-C remains ≥145 mg/dL.20,36)
When TG improves with weight control and lifestyle changes 
in children with hypertriglyceridemia, medication therapy is 
unnecessary. As a supportive medical therapy, the use of omega-3 
fatty acids is suggested along with lifestyle modification via the 
CHILD-2-TG, especially in children with hypertriglyceridemia. 
When the affected child has TG levels from 200–499 mg/dL and 
a non-HDL-C result ≥ 145 mg/dL, omega-3 fatty acid treatment 
may be considered.36) 
 However, safety issues remain unclear due to the limited ex-
perience with omega-3 fatty acids in children, which have only 
been used in a small number of cases.37) (Table 5)
Statins and bile acid-binding resins are the two main classes 
of medications currently used to treat this condition in pediatric 
patients. Commonly used medications are listed in Table 6. 
Statins that are approved by the U.S. Food and Drug Administra-
tion (FDA) in children older than 10 years include pravastatin, 
simvastatin, lovastatin, and atorvastatin. Cholesterol-absorption 
inhibitors, such as niacin and fibrates, are not yet approved by the 
US FDA.
A statin is recommended as the initial medication of choice 
for children with elevated LDL-C or non-HDL-C levels. Statins 
inhibit the rate-limiting enzyme β-hydroxy β-methylglutaryl-
CoA reductase and induce endogenous synthesis of cholesterol. 
Statins are effective at lowering cholesterol levels by 20%–50% 
below the baseline. They are also known to have minimal side 
effects and do not affect growth.31,38,39) The treatment regime 
should begin at the lowest dose given once daily at bedtime. 
Atorvastatin can be taken either in the morning or evening 
because of its long half-life. Before beginning statin treatment, 
baseline measurements of alanine aminotransferase, aspartate 
aminotransferase, and creatinine kinase should be obtained. Li-
ver function tests, creatinine kinase, and a fasting lipid profile 
should be repeated at 4 and 8 weeks after the initiation of therapy 
and then again every 3 to 6 months. If liver enzymes are more 
than 3 times the upper limit or the creatinine kinase is >10 times 
the upper limit of the reference range, the statin medication 
should be stopped.40,41) 
The target LDL-C value is typically <130 mg/dL, but if the 
patient is at high risk, such as with familial hypercholesterolemia 
or diabetes mellitus, the target LDL-C level should be maintained 
below 100 mg/dL. If target levels are not achieved within three 
months, the statin dose can be gradually increased to the maxi-
mum amount.
Since statins are potentially teratogenic, it is essential for phy-
sicians to confirm that adolescent girls are not pregnant before 
Table 5. Recommendations for pharmacological treatment of dyslipidemia
Age Treatment 
Birth–9 yr Pharmacological treatment is limited to children with homozygote familial hypercholesterolemia, LDL-C ≥400 mg/dL, primary 
hypertriglyceridemia (TG ≥500 mg/dL), cardiovascular disease, and cardiac transplantation. 
10–21 yr Refer to lipid specialist
LDL-C ≥250 mg/dL or TG ≥500 mg/dL
Statin treatment 
1) LDL-C ≥190 mg/dL
2) LDL-C 160–189 mg/dL, and a positive family history of premature CVD in first-degree relatives or at least one high-level risk factor 
or risk condition or at least 2 moderate-level risk factors or risk conditions
3) LDL-C ≥130–159 mg/dL, and at least 2 high-level risk factors or conditions or at least 1 high-level risk factor and 2 moderate-level 
risk factors or conditions
Omega-3 fish oil
TG ≥200–499 mg/dL, non-HDL-C ≥145 mg/dL
Statin, fibrates, or niacin may be considered
If non-HDL-C ≥145 mg/dL after LDL-C has reached the target level 
LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol.
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initiating statin therapy.
Bile acid sequestrants are the first line of therapy for children 
with dyslipidemia as these compounds are not absorbed syste-
mically.42) They work by preventing cholesterol reuptake in the 
enterohepatic circulation. However, cholestyramine and cole-
stipol are unpalatable and are associated with gastrointestinal 
side effects, including bloating, nausea, diarrhea, and constipa-
tion. Therefore, compliance with this type of therapy is generally 
poor. 
Ezetimibe (a cholesterol-absorption inhibitor) enters the en-
terohepatic circulation and reduces bile acid reuptake as well as 
cholesterol absorption. Ezetimibe is approved in children older 
than 10 years of age at a dosage of 10 mg/day as an adjuvant to 
statin therapy. In adults, ezetimibe has been shown to reduce the 
LDL-C by 20%.43) No studies have investigated the treatment 
of ezetimibe alone in children, but data regarding children’s 
experience with niacin and fibrates are also limited. 
Therefore, niacin, fibrates, and ezetimibe should only be ini-
tiated after consulting with a lipid specialist. When these drugs 
are used in combination in children, they exert an increased com-
bined effect, but the occurrence of side effects is not increased. 
Conclusions 
Atherosclerosis begins in childhood and can lead to CVD in 
adulthood. Early detection and proper management of dy-
slipidemia in children and adolescents are urgently needed 
to reduce adult CV morbidity. The 2017 Clinical Practice 
Guidelines for Dyslipidemia of Korean Children and Adoles-
cents are intended to help identify children who are at increased 
risk of CVD and may benefit from the early screening and 
intervention of dyslipidemia. These guidelines provide a schema-
tic approach that will help pediatricians make timely decisions 
regarding the screening and management of Korean children 
and adolescents with risks and conditions associated with ac-
celerated atherosclerosis. 
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